Non Small Cell Lung Cancer - osimertinib - EGFR L861Q + TP53 mutation + RB1 mutation

Association details:

Biomarker:	EGFR L861Q + TP53 mutation + RB1 mutation
Cancer:	Non Small Cell Lung Cancer
Drug:	Tagrisso (osimertinib) (EGFR inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C4 – Case Studies

Source:

Front Oncol

Title:

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review

Published date:

09/02/2021

Excerpt:

Here, we report the case of a 68-year-old man with advanced NSCLC with concurrent EGFR L861Q mutation as well as TP53 and RB1 mutations. The patient was treated with osimertinib as first-line therapy and achieved a remarkable progression-free survival of 15 months.

DOI:

10.3389/fonc.2021.731572